BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million. Mirus Bio, part of Gamma Biosciences, is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN®.

马萨诸塞州伯灵顿市。-（商业新闻短讯）--德国达姆施塔特默克公司（Merck KGaA）的美国和加拿大生命科学公司MilliporeSigma今天宣布签署最终协议，以6亿美元收购Mirus Bio。Mirus Bio是Gamma Biosciences的一部分，是一家总部位于美国威斯康星州麦迪逊的生命科学公司，专门从事转染试剂（如TransIT VirusGEN®）的开发和商业化。

Transfection reagents play a critical role in the production of viral vector-based gene therapies..

转染试剂在基于病毒载体的基因疗法的生产中起着至关重要的作用。。

“Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years1 and will continue to advance, with a projected growth of 30 percent until 20282,” said Matthias Heinzel, Member of the Executive Board and CEO Life Science, Merck KGaA, Darmstadt, Germany.

德国达姆施塔特默克公司生命科学执行委员会成员兼首席执行官马蒂亚斯·海因泽尔（MatthiasHeinzel）表示：“在过去10年中，基于病毒载体的细胞和基因疗法已经证明了其潜力，获得了20多个批准1，并将继续发展，预计到20282年将增长30%。”。

“This acquisition, combined with our comprehensive portfolio, enables us to provide a truly differentiated and integrated offering to meet the growing demand for these life-saving therapies.”.

“此次收购，再加上我们全面的投资组合，使我们能够提供真正差异化和集成化的产品，以满足对这些救生疗法日益增长的需求。”。

“We have been driving innovation in nucleic acid delivery for two decades,” said Dale Gordon, CEO of Mirus Bio. “MilliporeSigma’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.”.

Mirus Bio首席执行官戴尔·戈登（Dale Gordon）表示：“二十年来，我们一直在推动核酸输送方面的创新。MilliporeSigma的广泛投资组合、规模和全球影响力，加上我们领先的转染试剂，将有助于将我们的业务提升到更高的水平，并使我们能够为全球更多的客户，最终是患者提供服务。”。

MilliporeSigma’s Process Solutions business offers one of the broadest product portfolios in the industry and provides flexible solutions for viral vector manufacturing to advance cell and gene therapies from preclinical through commercial production. This comprehensive portfolio includes cell lines, cell culture media, processing chemicals and buffers, enzymes, as well as systems, filters, hardware and consumables to support every step of the viral vector manufacturing processes.

MilliporeSigma的过程解决方案业务提供了业界最广泛的产品组合之一，并为病毒载体制造提供了灵活的解决方案，以促进细胞和基因治疗从临床前到商业生产。该综合投资组合包括细胞系，细胞培养基，加工化学品和缓冲液，酶，以及系统，过滤器，硬件和耗材，以支持病毒载体制造过程的每一步。

Its expertise and portfolio covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus. Additionally, MilliporeSigma’s Life Science Services business offers both contract testing services and a suite of comprehensive CDMO services for viral vector manufacturing, leveraging three decades of experience supporting cell and gene therapies to de-risk the path to commercialization..

其专业知识和投资组合涵盖多种病毒载体类型，包括腺相关病毒，慢病毒和腺病毒。此外，MilliporeSigma的生命科学服务业务为病毒载体制造提供合同测试服务和一套全面的CDMO服务，利用三十年支持细胞和基因疗法的经验来降低商业化道路的风险。。

This deal is anticipated to close in Q3 of 2024 and is subject to regulatory clearance and other customary closing conditions.

该交易预计将于2024年第三季度完成，并受监管机构批准和其他惯例成交条件的约束。

About the Life Science business of Merck KGaA, Darmstadt, Germany

关于德国达姆施塔特默克公司的生命科学业务

The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 28,000 employees and more than 55 total manufacturing and testing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.

德国达姆施塔特默克公司（Merck KGaA）的生命科学业务在美国和加拿大作为MilliporeSigma运营，在全球拥有28000多名员工和55多个总制造和测试站点，拥有300000多种产品，专注于科学发现、生物制造和测试服务。

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics..

德国达姆施塔特默克公司是一家领先的科技公司，经营医疗保健、生命科学和电子产品。。

Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere.

大约63000名员工通过创造更快乐和可持续的生活方式，每天努力为数百万人的生活带来积极的影响。从提供加速药物开发和制造的产品和服务，以及发现治疗最具挑战性疾病的独特方法，到实现设备的智能化，该公司无处不在。

In 2023, Merck KGaA, Darmstadt, Germany, generated sales of € 21 billion in 65 countries..

2023年，德国达姆施塔特默克公司在65个国家的销售额达到210亿欧元。。

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics.

该公司在国际上拥有“默克”名称和商标的全球权利。唯一的例外是美国和加拿大，德国达姆施塔特默克公司（Merck KGaA）的业务部门在生命科学领域担任MilliporeSigma，在医疗保健领域担任EMD Serono，在电子领域担任EMD Electronics。

Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com..

自1668年成立以来，科学探索和负责任的创业精神一直是该公司技术和科学进步的关键。直到今天，创始家族仍然是这家上市公司的主要所有者。有关德国达姆施塔特默克公司的更多信息，请访问www.emdgroup.com。。

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.

关注Twitter@MilliporeSigma、Facebook@MilliporeSigma和LinkedIn上的MilliporeSigma。

All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email.

所有默克公司（Merck KGaA）、达姆施塔特（Darmstadt）的新闻稿均通过电子邮件分发，同时可在EMD集团网站上查阅。如果您是美国或加拿大居民，请访问www.emdgroup.com/subscribe再次注册您在线订阅此服务，因为我们新推出的地理定位需要电子邮件中的新链接。

You may later change your selection or discontinue this service..

您可以稍后更改选择或停止此服务。。

1 https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

1https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products